Trial · NCT02053116
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo | Week 0, 4 | |
| Secondary | Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo | Weeks 0 and 4 | |
| Secondary | Change from baseline in fasting plasma glucose | Weeks 0, 2, 4 and 6 | |
| Secondary | Change from baseline in Glycosylated Hemoglobin (HbA1c) | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in fasting total cholesterol | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in glucose AUC(0-5) during mixed meal tolerance test (MMTT) | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in insulin AUC(0-5) during mixed meal tolerance test (MMTT) | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in C-peptide AUC(0-5) during mixed meal tolerance test (MMTT) | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in ratio of AUC(0-5) insulin to AUC(0-5) glucose during the MMTT | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in ratio of AUC (0-5) C-peptide to AUC(0-5) glucose during the MMTT | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in homeostatic model assessment for insulin resistance (HOMA IR) | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in homeostatic model assessment for β-cell function (HOMA B) | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in low density lipoprotein cholesterol (LDL-C) | Weeks 0, 4 and 6 | |
| Secondary | Plasma concentrations for PF-05175157 | Weeks 2, 4 and 6 | |
| Secondary | Percent change from baseline in body weight | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in high density lipoprotein cholesterol (HDL-C) | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in triglycerides | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in non-HDL cholesterol | Weeks 0, 4 and 6 | |
| Secondary | Change from baseline in very low density lipoprotein (VLDL) | Weeks 0, 4 and 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02053116/registered